Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Neoadjuvant hormonal treatment for luminal breast cancer: Rationale, evidence and outcome

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.01.19
Views: 1495

Prof Hope Rugo - University of California, San Francisco, USA

Prof Hope Rugo speaks to ecancer at BGICC 2019 in Cairo about neoadjuvant hormone therapy as a way to treat luminal breast cancer.

She discusses some of the key outcomes from the session including some early biological markers of endocrine sensitivity, one being a fall in Ki-67, that tends to show more positive outcomes.

Prof Rugo hopes to see more widespread use of the PEPI score in order to look at endocrine sensitivity when choosing therapeutic options.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation